Richard E. Champlin

TL;DR: The first experience with the use of rituximab (Rituxan, Genentech, South San Francisco, CA, USA) for the treatment of PLS in an ASCT patient is described and the accumulated data regarding the transfusion requirement for patients with PLS after ASCT is reviewed.

TL;DR: Evidence is provided that naive and diverse CB T cells may be expanded ex vivo and warrant additional studies in the setting of human CB transplantation.

TL;DR: A simple technique to separate erythrocytes from bone marrow by sedimentation under gravity after addition of hydroxyethyl starch is described, which obviates the need for cumbersome and potentially hazardous large volume plasma exchange that is commonly utilized to deplete recipient isohaemagglutinins prior to transplantation.

TL;DR: The results provide a conceptual mechanistic basis for exploring this triple-drug combination in pretransplant conditioning therapy for allo-HSCT and show synergistic cytotoxicity in Bu-resistant AML KBM3/Bu250(6) cells.

TL;DR: To determine if ganciclovir given three times per week post-transplant is tolerable and effective for prevention of cytomegalovirus (CMV) infection in recipients of T cell-depleted marrow from related or unrelated donors, it is used as CMV prophylaxis for 51 adults who were CMV-seropos positive or had seropositive donors.